MORBIDITY & MORTALITY IN HTN

在一组血压控制水平相同的高危高血压患者中，血管紧张素II受体拮抗剂缬沙坦在降低急性心肌梗死、充血性心力衰竭和心脏死亡率方面比钙通道阻滞剂氨氯地平更有效。次要假设在相同的血压控制水平下，缬沙坦比钙通道阻滞剂氨氯地平在降低所有死因、脑血管发病率/死亡率和除急性心肌梗死/死亡率外的冠状动脉事件方面更有效。目的是开展一项研究，能够检测用缬沙坦80和160 mg治疗的高血压患者与用氨氯地平5和10 mg治疗的高血压患者之间心血管发病率和死亡率的15%差异，每日一次添加或不添加氢氯噻嗪。

Primary hypothesis In a group of high risk hypertensive patients for the same level of blood pressure control the angiotensin II receptor antagonist valsartan will be more efficacious in reducing acute myocardial infraction, congestive heart failure and cardiac mortality than the calcium channel blocker amlodipine. Secondary hypothesis For the same level of BP control valsartan will be more efficacious than the calcium channel blocker amlodipine in reducing all causes of death, cerebrovascular morbidity/mortality, and coronary events other than acute myocardial infarction/mortality. The objective is to execute a study capable of detecting a 15% difference in cardiovascular morbidity and mortality between a group of hypertensive patients treated with valsartan 80 and 160 mg, with or without the addition of hydrochlorathiazide once daily compared to a group treated with amlodipine 5 and 10 mg once daily, with or without addition of hydrochlorothiazide.